NEXGEL, Inc.

Equities

NXGL

US65344E1073

Pharmaceuticals

Market Closed - Nasdaq 04:30:00 2024-04-26 pm EDT 5-day change 1st Jan Change
2.21 USD -3.28% Intraday chart for NEXGEL, Inc. +1.84% +3.76%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
NEXGEL, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : NEXGEL, Inc., Q4 2023 Earnings Call, Apr 01, 2024
Earnings Flash (NXGL) NEXGEL Posts Q4 Revenue $1.1M MT
NEXGEL, Inc. Provides Revenue Guidance for the First Quarter of 2023 CI
NEXGEL, Inc. Announces Intention of Miranda J. Toledano to Resign as a Member of the Board of Directors, Effective as of March 31, 2024 CI
Top Premarket Decliners MT
Nexgel Subsidiary, Cg Converting and Packaging, Begins 12,000 Square Foot Expansion of Texas Facility to Support the Expected Growth in Product Demand in 2024 CI
NEXGEL, Inc. Announces Resignation of David Stefansky as Member of the Board of Directors CI
Nexgel Enters Deal With Stada Arzneimittel to Distribute OTC Products Across North America MT
NEXGEL, Inc. Announces Partnership with STADA Arzneimittel AG to Distribute and Commercialize Consumer Health OTC Products in North America CI
NEXGEL, Inc. acquired Kenkoderm from Olympus Trading Company, LLC for $1.1 million. CI
Tranche Update on NEXGEL, Inc.'s Equity Buyback Plan announced on December 7, 2022. CI
NEXGEL, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : NEXGEL, Inc., Q3 2023 Earnings Call, Nov 13, 2023
Earnings Flash (NXGL) NEXGEL Reports Q3 Revenue $1.2M, vs. Street Est of $1.2M MT
Sector Update: Health Care Stocks Higher in Afternoon Trading MT
NEXGEL Unit Executes Supply Agreement with AbbVie MT
NEXGEL, Inc. Secures Supply Agreement with AbbVie Inc CI
Tranche Update on NEXGEL, Inc.'s Equity Buyback Plan announced on December 7, 2022. CI
NEXGEL, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Transcript : NEXGEL, Inc., Q2 2023 Earnings Call, Aug 14, 2023
Earnings Flash (NXGL) NEXGEL Reports Q2 Revenue $1.2M, vs. Street Est of $1M MT
NEXGEL Partners With Enigma Health for Retail Distribution, Marketing Services in North America MT
Transcript : NEXGEL, Inc., Q1 2023 Earnings Call, May 15, 2023
Tranche Update on NEXGEL, Inc.'s Equity Buyback Plan announced on December 7, 2022. CI
Chart NEXGEL, Inc.
More charts
NexGel, Inc. is a provider of ultra-gentle, high-water-content hydrogels for healthcare and consumer applications. It is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. Its gels and its consumer products are manufactured using proprietary and non-proprietary mixing, coating, and crosslinking technologies. It markets under the brand names MedaGel and LumaGel Beauty. The products it sells under its MedaGel brand primarily relate to over the counter (OTC) remedy solutions, such as blister and pain applications; while the products it sells under its LumaGel Beauty brand primarily relate to beauty and cosmetic solutions, such as wrinkle and skin cream applications. The Company is also engaged in treating the symptoms of Psoriasis through its brand Kenkoderm.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.21 USD
Average target price
6 USD
Spread / Average Target
+171.49%
Consensus
  1. Stock Market
  2. Equities
  3. NXGL Stock
  4. News NEXGEL, Inc.
  5. Earnings Flash (NXGL) NEXGEL Reports Q3 Revenue $1.2M, vs. Street Est of $1.2M